Emmanuel Sánchez Díaz, Gabriel Levin, Beatriz Aristizabal, Andreína Fernandes, Florencia Noll, David Cantú, Fernando Heredia, Helena M Obermair, Rene Pareja
{"title":"Silicon dioxide, sodium selenite and citric acid vaginal gel, HPV infection, and cervical preinvasive disease: a narrative review.","authors":"Emmanuel Sánchez Díaz, Gabriel Levin, Beatriz Aristizabal, Andreína Fernandes, Florencia Noll, David Cantú, Fernando Heredia, Helena M Obermair, Rene Pareja","doi":"10.1016/j.ijgc.2025.102021","DOIUrl":"10.1016/j.ijgc.2025.102021","url":null,"abstract":"<p><p>Cervical cancer continues to be a major public health concern, particularly in low- and middle-income countries. It is mainly caused by persistent infection with human papillomavirus (HPV). Screening has been the most effective strategy to reduce mortality, but over the last 2 decades, vaccination has emerged as an important adjunct, helping to decrease incidence and mortality. Given the natural history of HPV infection, most low-grade lesions will spontaneously resolve over time; therefore, observation is the preferred approach for low-grade squamous intraepithelial lesions. Some authors have suggested that this period without intervention may cause anxiety among patients and physicians. A vaginal gel containing 10.0 mg of silicon dioxide, 24.8 mg citric acid, and 0.25 mg selenium per dose, marketed as DeflaGyn, Deflamin, or Deflamed, has been approved in Europe, the United Arab Emirates, Uzbekistan, and Colombia. A literature search was conducted to identify all published clinical trials on DeflaGyn. As of January 2025, 6 studies have been published: 1 retrospective study, 1 randomized clinical trial (RCT) with 2 post hoc analyses, 1 prospective non-randomized trial, and 1 in vitro study. A methodological risk-of-bias assessment was performed, revealing a number of domains with high or unknown risk of bias in the RCT and its post hoc analyses. This review aims to summarize the available evidence and perform a critical analysis of the research. Current evidence is insufficient to support its use for treating HPV infection or dysplasia.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102021"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brian M Slomovitz, Natalie Danziger, Julia C F Quintanilha, Andrew D Kelly, Gerald Li, Vivek Podder, Douglas I Lin, Ryon P Graf, Julia A Elvin, Thomas J Herzog
{"title":"Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer.","authors":"Brian M Slomovitz, Natalie Danziger, Julia C F Quintanilha, Andrew D Kelly, Gerald Li, Vivek Podder, Douglas I Lin, Ryon P Graf, Julia A Elvin, Thomas J Herzog","doi":"10.1016/j.ijgc.2025.102107","DOIUrl":"10.1016/j.ijgc.2025.102107","url":null,"abstract":"<p><strong>Objective: </strong>We sought to validate the prognostic utility of comprehensive genomic profiling (CGP)-based molecular stratification for patients with endometrial carcinoma and to assess co-occurring biomarkers across subtypes.</p><p><strong>Methods: </strong>This study included patients from a de-identified nationwide (US-based) endometrial cancer clinicogenomic database who underwent CGP testing as part of routine care. Molecular subtypes were classified as POLE mutated (POLEmut), MSI-H, TP53 mutated (TP53mut), and no specific molecular profile (NSMP). Time to next treatment and overall survival were compared between molecular subtypes, with multivariable Cox models adjusted for relevant covariables.</p><p><strong>Results: </strong>Of 1,139 evaluated patients with advanced or recurrent endometrial carcinoma, the prevalence of the 4 molecular subtypes was 1% POLEmut, 22% high microsatellite instability, 47% TP53mut, and 31% NSMP. Compared with NSMP patients, POLEmut patients had numerically more favorable time to next treatment (HR 0.50, 95% CI 0.21 to 1.21) and overall survival (HR 0.52, 95% CI 0.17 to 1.66). High microsatellite instability patients had similar time to next treatment (HR 1.08, 95% CI 0.89 to 1.30) and overall survival (HR 0.91, 95% CI 0.71 to 1.19) relative to NSMP patients. TP53mut patients had the least favorable outcomes for time to next treatment (compared with NSMP, HR 1.39, 95% CI 1.19 to 1.62) and overall survival (HR 2.15, 95% CI 1.77 to 2.61). In multivariable analysis, TP53mut status was associated with less favorable time to next treatment and overall survival. Frequencies of other biomarkers varied by molecular subtype.</p><p><strong>Conclusions: </strong>The Cancer Genome Atlas (TCGA)/Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular classifier for endometrial carcinoma can be recapitulated using CGP and provides prognostic stratification even within an advanced or recurrent disease cohort. CGP for molecular subclassification could support trial design and enrollment and inform treatment escalation or selection.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102107"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to: correspondence on effect of prior adjuvant radiotherapy on immunotherapy outcomes in recurrent endometrial cancer by Guo et al.","authors":"Tao Guo, Yuxi Zhao, Jia Zeng, Enyu Tang, Yuanyuan Zhang, Lingying Wu","doi":"10.1016/j.ijgc.2025.101999","DOIUrl":"10.1016/j.ijgc.2025.101999","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101999"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eugénie de Weck, Pierre Vassilakos, Ania Wisniak, Micol Murtas, Patrick Petignat, George Enow Orock
{"title":"Implementation of point-of-care cytology for the triage of human papillomavirus-positive women in Cameroon.","authors":"Eugénie de Weck, Pierre Vassilakos, Ania Wisniak, Micol Murtas, Patrick Petignat, George Enow Orock","doi":"10.1136/ijgc-2024-005849","DOIUrl":"10.1136/ijgc-2024-005849","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101840"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Duplication of inferior vena cava: a case of retroperitoneal secondary cytoreductive surgery.","authors":"Giulio Bonaldo, Vicente Bebia","doi":"10.1136/ijgc-2024-005902","DOIUrl":"10.1136/ijgc-2024-005902","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101890"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gottfried E Konecny, Tara M Davidson, Coriolan L Lebreton, Leah A Marsh, Deandra K Chetram, Hunter J Atkinson, Melissa C Larson, Ann L Oberg, Nabilah Abdelaal, Jordyn Silverstein, Aminah Jatoi, Anita Washburn, Jill Burton, Sean Dowdy, Liying Zhang, Dorothy Hallberg, Victor E Velculescu, Dennis J Slamon, Andrea E Wahner-Hendrickson
{"title":"Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer.","authors":"Gottfried E Konecny, Tara M Davidson, Coriolan L Lebreton, Leah A Marsh, Deandra K Chetram, Hunter J Atkinson, Melissa C Larson, Ann L Oberg, Nabilah Abdelaal, Jordyn Silverstein, Aminah Jatoi, Anita Washburn, Jill Burton, Sean Dowdy, Liying Zhang, Dorothy Hallberg, Victor E Velculescu, Dennis J Slamon, Andrea E Wahner-Hendrickson","doi":"10.1016/j.ijgc.2025.102028","DOIUrl":"10.1016/j.ijgc.2025.102028","url":null,"abstract":"<p><strong>Objective: </strong>We describe a phase II clinical trial evaluating the safety and efficacy of the oral CDK4/6 inhibitor palbociclib in patients with recurrent ovarian cancer.</p><p><strong>Methods: </strong>Eligible patients with Response Evaluation Criteria in Solid Tumors (RECIST) and/or CA-125 measurable recurrent ovarian cancer were treated with oral palbociclib 125 mg daily for 21 days of a 28-day cycle. Patients with hormone receptor-positive tumors were allowed to concurrently receive an aromatase inhibitor. The primary endpoint was the biochemical response rate, determined by CA-125 response based on Gynecologic Cancer InterGroup criteria. Genomic analyses were performed using targeted next-generation sequencing.</p><p><strong>Results: </strong>The biochemical response rate among 40 patients was 8.3% (95% CI 2.2 to 23.6), and the objective response rate by CA-125 criteria and/or RECIST was 10.5% (95% CI 3.4 to 25.7). Median progression-free survival was 3.2 months. Progression-free survival rates at 6 and 12 months were 25% and 7.5%, respectively. Two patients diagnosed with recurrent low-grade serous ovarian cancer experienced long-term disease stabilization for more than 37 and 9 months, triggering a review of 12 additional low-grade serous ovarian cancer patients treated outside of the phase II trial. Exploratory tumor genomic profiling revealed potential predictors of sensitivity (CDKN2A deletion) or resistance (CCNE1 amplification or RB1 deletion), which require additional independent validation.</p><p><strong>Conclusions: </strong>Palbociclib demonstrated only modest clinical activity in unselected patients with ovarian cancer. However, cyclin-dependent kinases 4/6 inhibition showed promising clinical activity in low-grade serous ovarian cancer, warranting further study in this subtype. Further biomarker analyses may facilitate patient selection in high-grade serous ovarian cancer.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102028"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra H Smick, Lindsay Brennan, Jordyn Silverstein, Ritu Salani, Gottfried Konecny, Dana M Chase
{"title":"Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.","authors":"Alexandra H Smick, Lindsay Brennan, Jordyn Silverstein, Ritu Salani, Gottfried Konecny, Dana M Chase","doi":"10.1016/j.ijgc.2025.102016","DOIUrl":"10.1016/j.ijgc.2025.102016","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate prescribing patterns, toxicities, and outcomes among patients receiving mirvetuximab for platinum-resistant ovarian cancer.</p><p><strong>Methods: </strong>This retrospective study included patients with platinum-resistant ovarian cancer with high folate receptor alpha expression treated with mirvetuximab at a single institution (2018-2023). Patients were categorized based on treatment immediately preceding mirvetuximab: the taxane group received taxane treatment; the non-taxane group received other therapy. An age-matched cohort of platinum-resistant patients not treated with mirvetuximab was included for survival comparison. Statistical analyses included descriptive statistics, Kaplan-Meier curves, log-rank tests, Wilcoxon rank-sum tests, and Cox models.</p><p><strong>Results: </strong>Forty-one patients received mirvetuximab, with a median of 8 cycles (range; 1-47). Grade ≥3 adverse events included ocular (n = 6; 15%), hematologic (n = 1; 2%), neuropathy (n = 1; 2%), and pneumonitis (n = 1; 2%). Dose reductions and delays occurred in 26 (63%) and 21 (51%) patients, respectively. Mirvetuximab was discontinued in 40 patients (98%), most commonly due to disease progression (n = 35; 88%). Mirvetuximab-treated patients had longer median overall survival from diagnosis compared to the age-matched cohort without mirvetuximab exposure (83.12 vs 52.14 months; HR 0.34, 95% CI 0.18 to 0.64, p < .001). Among patients who received taxane therapy immediately before mirvetuximab (n = 9), average treatment duration was 5 months (9 cycles), with no grade ≥3 neuropathy. In those who received a non-taxane regimen immediately before mirvetuximab (n = 32), average treatment duration was 6 months (8 cycles), with 1 patient (3%) experiencing grade ≥3 neuropathy. Median progression-free survival was similar between groups (5.49 vs 6.28 months; HR 1.30, 95% CI 0.61 to 2.78, p = .50), but overall survival was shorter in the taxane group (11.28 vs 21.02 months; HR 2.47, 95% CI 1.01 to 6.04, p = .048).</p><p><strong>Conclusions: </strong>Real-world experience with mirvetuximab demonstrated a favorable safety profile and clinical benefit in platinum-resistant ovarian cancer. Taxane therapy immediately preceding mirvetuximab was associated with shorter overall survival but not increased neurotoxicity.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102016"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correspondence on \"the effect of prior adjuvant radiotherapy on immunotherapy outcomes in recurrent endometrial cancer\" by Guo et al.","authors":"Gabriel Levin, Shuk On Annie Leung","doi":"10.1016/j.ijgc.2025.101963","DOIUrl":"10.1016/j.ijgc.2025.101963","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101963"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Checkpoint inhibitors in ovarian cancer maintenance: a promise not fulfilled.","authors":"Renata Arakelian, Luiza Andrade Mussi, Mariana Carvalho Gouveia, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.102037","DOIUrl":"10.1016/j.ijgc.2025.102037","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102037"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tiermes Marina, Víctor Lago, Pablo Padilla-Iserte, Berta Díaz-Feijoo, Santiago Domingo
{"title":"10-step technique for hepatic mobilization: essential anatomy and surgical approach.","authors":"Tiermes Marina, Víctor Lago, Pablo Padilla-Iserte, Berta Díaz-Feijoo, Santiago Domingo","doi":"10.1016/j.ijgc.2025.102031","DOIUrl":"10.1016/j.ijgc.2025.102031","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102031"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}